A Model to Assess the Outcomes Associated With Dementia With Lewy Bodies

被引:1
作者
Espinosa, Robert [1 ]
Davis, Matthew [1 ]
Johnson, Scott [1 ]
Cline, Stephanie [2 ]
Weintraub, Daniel [3 ,4 ]
机构
[1] Medicus Econ, Milton, MA USA
[2] Med Univ South Carolina, Dept Healthcare Leadership & Management, Charleston, SC 29425 USA
[3] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[4] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA
基金
美国国家卫生研究院;
关键词
dementia with Lewy bodies; transition probabilities; disease progression; outcomes;
D O I
10.1097/WAD.0000000000000412
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Research investigating outcomes associated with dementia with Lewy bodies (DLB) disease progression is scarce. Developing models of DLB disease progression will provide information on the burden of disease and facilitate the evaluation of treatments for DLB from a clinical and cost perspective. Methods: Longitudinal, cognitive evaluation data were utilized in order to identify distinct health states for DLB and to estimate transition probabilities across the DLB disease continuum. These probabilities were applied to a health state transition model to evaluate disease progression and associated outcomes for a closed cohort over a fixed time horizon. The effect of a reduction in the risk of disease progression on outcomes was assessed. Results: Estimated transition probabilities indicate that a patient >60 years of age with mild DLB has a 54%, 30%, 4%, and 12% chance of remaining mild, progressing to severe DLB, being institutionalized, and dying after 1 year, respectively. Reducing the annual risk of transitioning from mild to severe DLB by 40% decreased time institutionalized and increased time to death. Conclusions: This study used real-world longitudinal data to create a clinically relevant DLB disease progression model. Reducing the rate of disease progression resulted in meaningful benefits with potentially significant public health implications.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 30 条
[1]  
Alzheimer's Association, DEMENTIA LEWY BODIES
[2]   The National Alzheimer's Coordinating Center (NACC) database: The uniform data set [J].
Beekly, Duane L. ;
Ramos, Erin M. ;
Lee, William W. ;
Deitrich, Woodrow D. ;
Jacka, Mary E. ;
Wu, Joylee ;
Hubbard, Janene L. ;
Koepsell, Thomas D. ;
Morris, John C. ;
Kukull, Walter A. .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2007, 21 (03) :249-258
[3]   Comprehensive treatment of dementia with Lewy bodies [J].
Boot, Brendon P. .
ALZHEIMERS RESEARCH & THERAPY, 2015, 7
[4]   Institutionalization risk and costs associated with agitation in Alzheimer's disease [J].
Cloutier, Martin ;
Gauthier-Loiselle, Marjolaine ;
Gagnon-Sanschagrin, Patrick ;
Guerin, Annie ;
Hartry, Ann ;
Baker, Ross A. ;
Duffy, Ruth ;
Gwin, Keva ;
Aigbogun, Myrlene Sanon .
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2019, 5 (01) :851-861
[5]   Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia [J].
Davis, Matthew ;
O'Connell, Thomas ;
Johnson, Scott ;
Cline, Stephanie ;
Merikle, Elizabeth ;
Martenyi, Ferenc ;
Simpson, Kit .
CURRENT ALZHEIMER RESEARCH, 2018, 15 (08) :777-788
[6]   Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies [J].
Gustavsson, Anders ;
Van der Putt, Rohan ;
Jonsson, Linus ;
McShane, Rupert .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2009, 24 (10) :1072-1078
[7]   Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease [J].
Hanyu, H. ;
Sato, T. ;
Hirao, K. ;
Kanetaka, H. ;
Sakurai, H. ;
Iwamoto, T. .
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (02) :212-217
[8]   Extrapyramidal Signs by Dementia Severity in Alzheimer Disease and Dementia With Lewy Bodies [J].
Kaur, Berneet ;
Harvey, Danielle J. ;
DeCarli, Charles S. ;
Zhang, Lin ;
Sabbagh, Marwan N. ;
Olichney, John M. .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2013, 27 (03) :226-232
[9]   A Markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease [J].
Kirbach, Stephanie ;
Simpson, Kit ;
Nietert, Paul J. ;
Mintzer, Jacobo .
CLINICAL DRUG INVESTIGATION, 2008, 28 (05) :291-303
[10]  
Lewy Body Dementia Association, Diagnosing and managing Lewy body dementia